Companies appear wary of developing drugs for gram-negative bacteria

02/28/2010 | New York Times (tiered subscription model), The

Treatments for gram-negative bacteria are rarely pursued by drugmakers because of the bacteria's drug resistance, according to The New York Times. The lack of drugs also stems from the reluctance of developers to invest in antibiotics. The few candidates against gram-negative infection have increased in value, and big companies are licensing them from Calixa Therapeutics and other smaller firms.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations